Explore the full report
- The growth forces reshaping life sciences operations
- How system needs change from preclinical to commercialization
- Which ERP capabilities matter most at each stage
- How AI-ready ERP connects live data, governed access, and reporting
- Why implementation, validation, and compliance planning matter before scale exposes the gaps
Life sciences organizations are under increasing pressure to scale quickly while navigating regulatory complexity, limited resources, and evolving operational demands. Companies can progress from preclinical research and clinical development to commercialization faster than their systems can keep up.
It's important to establish a foundation that can evolve alongside your business. This is especially true as you build processes to grow: strengthening financial visibility, streamlining procurement, managing supply chain complexity, maintaining compliance, and improving decision-making.
Growth changes what systems need to do
Early-stage companies often prioritize speed, cash management, grant compliance, investor reporting, and R&D cost tracking. A lean back office may work while the organization focuses on discovery, intellectual property, and preclinical progress.
Clinical development adds new demands. Multisite trials, contract research organization spend, filings, public company readiness, and compliance readiness increase the need for stronger processes and better data.
Commercialization adds another layer. Revenue recognition, pricing and rebate complexity, pharmacovigilance, lot traceability, quality management, contract manufacturing organization (CMO) coordination, and third-party logistics (3PL) integration require a more connected operating model.




